Skip to content
Calculator

What happens when you stack them?

Choose up to six peptides or drugs, and any prescription medicines you take. The analyzer checks them against interactions recorded from FDA labels and published studies, a label rule against combining GLP-1 drugs, recorded effects on blood sugar and blood pressure, WADA status, and the evidence grade of each one, and it lists what has never been checked. Every flag shows where it comes from. It reports what is recorded; it cannot tell you a combination is safe, and it is not a substitute for a prescriber or pharmacist.

Your prescription medicines

Optional. Each one is checked against each component: a flag only where a drug label or a published study says so; otherwise no published interaction found, or unknown.

696 compounds; 153 with interactions recorded from a label or study; 28 prescription medicines, 234 compound-and-medicine pairs sourced to a label or study. Related: the interaction matrix, the interaction checker and serious reactions to injected peptides.

How this tool works · sources read November 3, 2026 · Grey Peptides Editorial Board

What the analyzer checks

Peptides are often discussed in combination, as blends in one vial or as 'stacks' of separate vials. The questions are always the same: do any of these interact, do any of them do the same thing twice, and is any of it banned in my sport? The Stack Safety Analyzer answers those questions with sources, and only with sources. Choose up to six compounds from the encyclopedia, and any prescription medicines you take, and it checks them six ways.

First, label rules: the prescribing information for Wegovy and Zepbound both say the drug should not be combined with another GLP-1 receptor agonist 1 2, so any stack containing two GLP-1 drugs is flagged with those quotations. Second, recorded interactions: our interaction matrix holds interactions taken from FDA labels or published studies for 153 compounds, and the analyzer flags any recorded interaction that names another compound on your list, by name, alias or class. Third, shared concerns: components whose recorded interactions affect blood sugar or blood pressure are tallied together. Fourth, sport: anything on WADA's 2026 Prohibited List is named. Fifth, gaps: anything never reviewed, or reviewed with nothing found, is listed rather than hidden. Sixth, your prescription medicines, described below.

Where the flags come from

The analyzer has no opinions of its own. Its interaction data is the same interaction matrix the site publishes: 81 compounds whose FDA label was read for interactions, cited to the label version; 72 with at least one published interaction study, cited by PubMed ID, many of them animal or laboratory studies, as each record says; and 543 where a recorded PubMed search found no interaction study of the compound. The text of each flag is the matrix's own wording, and each carries its citation underneath.

Class matching is deliberately narrow. A label that warns about 'other diabetes drugs' or 'insulin' is matched to GLP-1 drugs and insulins on your list, because those labels mean exactly that; a warning about 'oral medications' or 'drugs metabolised by cytochrome P450 enzymes' is shown in the component's record but is not matched to anything, because no entry's data says which peptides fall into those groups. The GLP-1 rule applies to entries whose class description names them as GLP-1 receptor agonists, and the build checks that the label sentences it quotes are still in the labels we hold.

Your prescription medicines

Since November 3, 2026 the analyzer also takes up to four prescription medicines, chosen from 28 common medicines and classes: insulin, sulfonylureas and metformin; warfarin, the DOACs and antiplatelet drugs; SSRIs, SNRIs, tricyclics, lithium and atypical antipsychotics; levothyroxine, oral contraceptives, oral estrogen and corticosteroids; ACE inhibitors, ARBs, beta-blockers, diuretics, digoxin and statins; PDE5 inhibitors; and naltrexone, opioids, NSAIDs, benzodiazepines, antiepileptics and cyclosporine, which are there because a peptide label's Drug Interactions section names them. Each medicine is checked against each component, and the answer is one of three.

A flag appears only where an FDA label section or a published study addresses that pair, and it quotes the label sentence with its DailyMed set, version and date, or cites the study by PubMed ID. The data holds 234 such pairs for 44 compounds, read from 46 cached labels and 6 studies: 216 cautions or conflicts and 18 findings that are information rather than warnings, most of them no clinically significant change. The labels of GLP-1 medicines, for instance, warn of low blood sugar with insulin or sulfonylureas; tirzepatide's tell people on the pill to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and after each dose increase; growth hormone and tesamorelin labels warn that people on steroid replacement may need higher doses; desmopressin's warns of low blood sodium with SSRIs, tricyclics, opioids, NSAIDs and some antiepileptics; and Vyleesi's says to avoid bremelanotide with oral naltrexone. Where the only evidence is in animals, the flag says so: for melanotan II, a mouse study in which metoprolol blocked its rise in blood pressure.

Otherwise the pair reads no published interaction found, when a recorded PubMed search for interaction studies of the compound with any drug found none in people (543 compounds), or a search for that pair found nothing; or unknown, when the compound has a label or studies but none of them addresses the medicine and no search for the pair has been recorded (153 compounds). Neither is a statement that the pair is safe. A warning about a medicine is never extended to another medicine in its class unless the label names the class.

Reading the results

Red-edged flags are the strongest: a label saying a combination is not recommended, or a WADA prohibition. Amber flags are recorded interactions between components, and gaps in what has been checked. Blue flags are information: two components with recorded effects on the same thing, such as blood sugar, or two entries described as acting on the same receptor. A shared target is not proof of a problem, and the analyzer says so; it is a reason to ask whether the combination adds anything, or adds risk.

The component table at the end gives each compound's regulatory status, evidence grade and interaction record. A stack of compounds graded 'low', with interaction records that read 'unreviewed', is a stack nobody has studied, whatever else the analyzer finds.

Why 'no flags' is not 'safe'

The most common result for research-peptide stacks is no recorded interaction at all, and it is the most misleading one if read carelessly. Of the 296 encyclopedia entries approved nowhere (research-only), 275 are in the 'none found' group: a recorded search for interaction studies returned nothing about them. Nothing found means nothing has been studied, not that nothing happens. The analyzer prints that distinction for every component, and our article on serious reactions to injected peptides shows how a multi-peptide injection can go wrong in ways no one can trace afterwards.

Combining compounds also makes side effects impossible to attribute. If something goes wrong on a six-peptide stack, there is no way to tell which component, or which combination, caused it, and 232 of those 296 research-only entries are graded low for human evidence even on their own.

Stacks and blends

A stack can be separate vials or one blended vial. If it is a blend, every draw delivers every component in a fixed ratio, so you cannot reduce one without reducing all of them. The Blend Calculator works out what each draw contains, and our article on blend dose maths explains why no blend has an evidence-based dose. Use the analyzer to see what is known about the combination, and the calculator to see what is in the syringe.

Sources

  1. Novo Nordisk. Wegovy (semaglutide) US prescribing information, Limitations of Use: concomitant use with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended (DailyMed set ee06186f, effective June 18, 2026); read October 3, 2026, re-read October 27, 2026.
  2. Eli Lilly. Zepbound (tirzepatide) US prescribing information, Limitations of Use (DailyMed set 487cd7e7, effective August 28, 2026); read October 3, 2026.

This explainer describes how the tool works and what its numbers rest on. It is not medical advice and does not recommend any dose or product.